Cipla Limited (CIPLA) — Board Meeting | 23 January 2026(3 announcements)
Cipla Limited's board approved changes to Key Managerial Personnel (KMPs) effective 1st April 2026. The restructuring includes appointments of Mr Achin Gupta as Managing Director and Global CEO, Mr Ashish Adukia as Global CFO, Mr Rajendra Chopra as Company Secretary, and Ms Meera Vanjari as Global General Counsel. The board meeting was held on 23rd January 2026.
Cipla's Board approved the re-appointment of Mr. P R Ramesh as Independent Director for a second five-year term from 1st July 2026 to 30th June 2031, subject to shareholder approval. Ramesh, a 45-year veteran with Deloitte Global Board experience and current Audit Committee chair at Cipla, brings expertise across manufacturing, banking, technology, and consumer sectors. He currently serves on boards of Air India, L&T, Nestlé India, and other leading companies.
Cipla Limited reported Q3 FY2025-26 consolidated revenue of ₹7,074.48 crores with net profit of ₹674.25 crores. The quarter included a ₹275.91 crore exceptional charge for new labour code implementation and the ₹1,107.28 crore Galvus trademark license acquisition from Novartis. The company completed the ₹110.65 crore acquisition of Inzpera Healthscience. Ongoing NPPA litigation poses ₹2,011 crore net outstanding demands. Nine-month revenue reached ₹21,621.39 crores.
About Cipla Limited (CIPLA)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when CIPLA files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track CIPLA — Free💡 Ask AI about this filing
📊 More CIPLA filings
- Announcement — 11 August 2026 Cipla announced its ESG ratings from SES and NSE on August 11, 2026, showing a slight improvement in...
- Announcement — 4 August 2026 Cipla announced that its US subsidiary InvaGen closed a USFDA inspection at its Hauppauge facility, ...
- 🔴 Corporate Action — 31 July 2026 Cipla announced the allotment of 7,850 fully paid-up equity shares of INR 2 each under its ESOS 2013...
- Announcement — 27 July 2026 Cipla announced U.S. FDA approval for its generic version of Advair Diskus across all three strength...
- 🔴 Financial Results — 23 July 2026 Cipla reported consolidated revenue of INR 7,119 crores for Q1 FY27, up 2% YoY, with One India busin...
🔥 Also filed on 23 January 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when CIPLA files new disclosures
Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track CIPLA — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research